GSGTF (Gensight Biologics) Buyback Yield %: -55.03 (As of Jul. 01, 2026)


What is Gensight Biologics Buyback Yield %?

Gensight Biologics GSGTF Buyback Yield % is -55.03 as of Jul. 01, 2026. The stock has 8 warning signs investors should review. Among 745 Biotechnology companies, Gensight Biologics ranks worse than 84.16% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Gensight Biologics's current buyback yield was -55.03%.

Gensight Biologics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics Buyback Yield % Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 0.11 -13.99 -59.57 -29.08

Gensight Biologics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.11 -49.12 -50.57 -18.93 -45.21

GSGTF vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Gensight Biologics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's Buyback Yield % falls into.


Gensight Biologics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Gensight Biologics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 12.178) / 41.882832
=-29.08%

Gensight Biologics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 12.178) / 41.882832
=-29.08%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -55.03 mean?
Gensight Biologics (GSGTF) has a Buyback Yield % of -55.03 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #627 out of 745 companies in the Biotechnology industry, placing it in the top 84.2%.
Is Gensight Biologics' Buyback Yield % too high?
Gensight Biologics' current Buyback Yield % is -55.03. Based on the distribution chart, Gensight Biologics ranks #627 out of 745 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Gensight Biologics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #627 out of 745 companies for Buyback Yield %. This places Gensight Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current Buyback Yield % is -55.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current Buyback Yield % is -55.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current Buyback Yield % is -55.03 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.